Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceGore Excluder Conformable AAA Endoprosthesis (CEXC)
Generic NameSYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
ApplicantW. L. Gore and Associates, Inc.
32360 N. North Valley Parkway
Phoenix, AZ 85085
PMA NumberP200030
Date Received06/29/2020
Decision Date12/22/2020
Product Code MIH 
Docket Number 20M-2339
Notice Date 12/23/2020
Advisory Committee Cardiovascular
Clinical TrialsNCT02489539
Expedited Review Granted? No
Combination ProductNo
Approval Order Statement  
Approval for Gore Excluder Conformable AAA Endoprosthesis (EXCC)This device is indicated to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below:1) Adequate iliac / femoral access;2) Infrarenal aortic neck treatment diameter range of 16–32 mm;3) A minimum aortic neck length of 15 mm when proximal aortic neck angulation is =<60 degrees; and4) Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Labeling Part 2
Post-Approval StudyShow Report Schedule and Study Progress
Supplements:  S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S011 
S012 S013 S014 S015 
-
-